Figure 1. Flow of patients included in the primary analysis dataset. ^aData from eculizumab trial C08-003 were excluded owing to the study being conducted in a different patient population (patients were receiving long-term maintenance plasma therapy at baseline and, consequently, had normal platelet counts). ^b“All patients” represents the maximum possible number of patients before the application of missing data restrictions for each subgroup by treatment. ^cPatient numbers for primary analysis represent patients with complete cases for propensity score variables, with a maximum of one missing laboratory measure and outcome data within 56 days of the 6-month endpoint.